Climb Bio (NASDAQ:CLYM – Free Report) had its price target boosted by Wedbush from $17.00 to $20.00 in a research report report published on Monday,Benzinga reports. They currently have an outperform rating on the stock.
Several other brokerages have also recently issued reports on CLYM. Robert W. Baird set a $21.00 target price on Climb Bio in a research report on Wednesday, May 6th. Guggenheim initiated coverage on Climb Bio in a research report on Monday, June 8th. They issued a “buy” rating and a $35.00 price target for the company. Chardan Capital began coverage on Climb Bio in a research note on Tuesday, May 5th. They set a “buy” rating and a $22.00 price objective on the stock. Mizuho initiated coverage on shares of Climb Bio in a report on Wednesday, April 15th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, Oppenheimer upped their target price on shares of Climb Bio from $10.00 to $18.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Climb Bio presently has an average rating of “Buy” and a consensus price target of $22.00.
Check Out Our Latest Stock Analysis on CLYM
Climb Bio Price Performance
Climb Bio (NASDAQ:CLYM – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. As a group, analysts expect that Climb Bio will post -0.87 EPS for the current year.
Hedge Funds Weigh In On Climb Bio
Institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP increased its position in shares of Climb Bio by 71.0% during the first quarter. Seven Fleet Capital Management LP now owns 130,654 shares of the company’s stock valued at $895,000 after acquiring an additional 54,254 shares during the last quarter. Bank of America Corp DE boosted its position in Climb Bio by 945.2% in the first quarter. Bank of America Corp DE now owns 52,921 shares of the company’s stock worth $363,000 after purchasing an additional 47,858 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Climb Bio by 11.2% in the first quarter. The Manufacturers Life Insurance Company now owns 156,317 shares of the company’s stock worth $1,071,000 after purchasing an additional 15,700 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Climb Bio in the 1st quarter valued at $715,000. Finally, Hsbc Holdings PLC grew its stake in Climb Bio by 107.2% in the 4th quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock valued at $99,000 after purchasing an additional 12,800 shares during the period. 69.76% of the stock is owned by institutional investors.
About Climb Bio
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
Recommended Stories
- Five stocks we like better than Climb Bio
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
